EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtOpen Access · CC BY 4.0

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Before and After Liver Transplantation: A Systematic Review

Francesco Dituri iD, Livianna Carrieri iD, Maria Mosaico iD, Giusi Caragnano iD, Erica Villa iD

Cancers · 17.04.2026 · 18 (8) · 1282

DOI: 10.3390/cancers18081282 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 17.04.2026. Verfasst von Francesco Dituri und 4 weiteren Autor:innen. Beteiligte Einrichtung: National Institute of Gastroenterology, IRCCS "S. De Bellis" Research Hospital, Via Turi 27, 70013 Castellana Grotte, Italy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Association for Cancer Research, Ministero della Salute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Immune checkpoint inhibitors (ICIs) are increasingly used in hepatocellular carcinoma (HCC), but their application around liver transplantation (LT) remains controversial because checkpoint blockade may enhance antitumor immunity while disrupting graft tolerance. We systematically reviewed the available evidence on ICI exposure before LT and ICI therapy after LT for recurrent HCC.

Methods

A PRISMA-guided systematic review with qualitative synthesis was performed. PubMed/MEDLINE, Embase, and Web of Science were searched from inception to 15 March 2026. Studies including adult patients with HCC treated with PD-1-, PD-L1-, and/or CTLA-4-targeting ICIs before LT or after LT for recurrent HCC were eligible.

Results

Fifty-one studies were included. In the pre-LT setting, 25 studies reported 576 transplanted patients. Acute allograft rejection occurred in approximately 22% and graft loss in 3.8%, and shorter washout intervals were consistently associated with higher rejection risk. In the post-LT setting, 26 studies reported 117 recipients treated with ICIs; at least 22 rejection episodes (18.8%) were described, usually within 2–4 weeks of treatment initiation, with limited and inconsistent antitumor benefit.

Conclusions

Pre-LT ICI use appears feasible in selected patients when adequate washout is respected. Post-LT ICI therapy remains high risk and should be reserved for highly selected cases within a multidisciplinary framework.

Schlagwörter

Stichwörter der Autor:innen

allograft rejectionbridging therapygraft losshepatocellular carcinomaimmune checkpoint inhibitorsliver transplantationwashout interval

Autor:innen und Institutionen

  • National Institute of Gastroenterology, IRCCS "S. De Bellis" Research Hospital, Via Turi 27, 70013 Castellana Grotte, Italy.

ORCID-Profile: Francesco Dituri, Livianna Carrieri, Maria Mosaico, Giusi Caragnano, Erica Villa

Förderung

  • Italian Association for Cancer Research
  • Ministero della Salute

Zitieren

APA

Dituri, F., Carrieri, L., Mosaico, M., Caragnano, G., & Villa, E. (2026). Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Before and After Liver Transplantation: A Systematic Review. Cancers, 18(8), 1282. https://doi.org/10.3390/cancers18081282

Vancouver

Dituri F, Carrieri L, Mosaico M, Caragnano G, Villa E. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Before and After Liver Transplantation: A Systematic Review. Cancers. 2026;18(8):1282. doi:10.3390/cancers18081282

BibTeX
@article{Dituri2026,
  author = {Dituri, Francesco and Carrieri, Livianna and Mosaico, Maria and Caragnano, Giusi and Villa, Erica},
  title = {Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Before and After Liver Transplantation: A Systematic Review},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {8},
  pages = {1282},
  doi = {10.3390/cancers18081282}
}
Kostenlos starten →